Dulaglutide or Tirzepatide, hepatitis C treatment, long COVID-19 treatment, and biopharma updates

from TT HealthWatch · host Christina Acosta

Program notes:0:38 Migrating biopharma industry1:36 Early stage development2:36 Need to replicate studies3:23 Treatment for fatigue from long Covid4:25 Fluvoxamine or metformin5:25 Only fluvoxamine helped6:25 Only for fatigue6:35 How treatments for hepatitis C have been used7:36 Number of people receiving treatment declining8:36 Need a better system9:16 Dulaglutide or tirzepatide and patient reported outcomes10:17 Quality of life metrics11:43 End

Episode metadata supplied by the publisher feed · Published Apr 3, 2026

Embed this episode

Attribution link and audio player

What this episode covers

This week's topics include dulaglutide or tirzepatide, hepatitis C treatment, drugs for fatigue in long Covid, and biopharma changes around the world.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Dulaglutide or Tirzepatide, hepatitis C treatment, long COVID-19 treatment, and biopharma updates

0:00 11:44

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TT HealthWatch?

This episode is 11 minutes long.

When was this TT HealthWatch episode published?

This episode was published on April 3, 2026.

Can I download this TT HealthWatch episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!